April 5 (Reuters) - The U.S. Food and drug Administration on Friday allowed use of Bristol-Myers Squibb and 2seventybio's cell therapy Abecma in less severely affected patients with a type of blood cancer.

The health regulator is also reviewing another cancer cell therapy, Carvykti, from Johnson & Johnson and its partner Legend Biotech for use in less severely affected patients. (Reporting by Sneha S K and Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)